113 related articles for article (PubMed ID: 9473127)
1. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.
Sato K; Kawasaki T; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Eur J Pharmacol; 1997 Nov; 339(2-3):141-6. PubMed ID: 9473127
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time.
Sato K; Kaku S; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T; Iizumi Y
Eur J Pharmacol; 1998 Jul; 352(1):59-63. PubMed ID: 9718268
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Ichihara M; Matsumoto Y
Eur J Pharmacol; 1998 May; 350(1):87-91. PubMed ID: 9683019
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
8. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
10. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Kawasaki T; Sato K; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
Thromb Haemost; 1998 Apr; 79(4):859-64. PubMed ID: 9569205
[TBL] [Abstract][Full Text] [Related]
11. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Schumacher WA; Heran CL; Steinbacher TE
J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
[TBL] [Abstract][Full Text] [Related]
13. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.
Giardino EC; Haertlein BJ; de Garavilla L; Costanzo MJ; Damiano BP; Andrade-Gordon P; Maryanoff BE
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):128-34. PubMed ID: 20010091
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Kawasaki T; Sato K; Sakai Y; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
Thromb Haemost; 1998 Feb; 79(2):410-6. PubMed ID: 9493600
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
Hayashi M; Matsuo A; Nakamoto H; Aisaka K
Eur J Pharmacol; 2001 Jan; 412(1):61-6. PubMed ID: 11166737
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
